Kit or device for detecting malignant brain tumor and method for detecting same

A technology of malignant brain tumors and kits, which is applied in the field of detection of malignant brain tumors and can solve the problems of lack of practicability

Inactive Publication Date: 2018-11-23
TORAY IND INC +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, regarding the diagnostic method described in Patent Document 1, there is no description of the specific accuracy, sensitivity, specificity, and other discriminative performance and means for distinguishing brain tumors, and it lacks industrial applicability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit or device for detecting malignant brain tumor and method for detecting same
  • Kit or device for detecting malignant brain tumor and method for detecting same
  • Kit or device for detecting malignant brain tumor and method for detecting same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0286] The present invention is further specifically illustrated by the following examples. However, the scope of the present invention is not limited by this example.

reference example 1

[0288]

[0289] Glioma (astrocytoma, oligodendroglioma, oligodendroglioma, oligodendroglioma, oligodendroglioma, oligodendrocyte astrocytoma, Stemocyte tumor) patients (23 cases of grade II, 25 cases of grade III, and 50 cases of grade IV) and 14 patients of meningioma who were benign brain tumors were treated with Venoject II vacuum blood collection tube VP-AS109K60 (Terumo Co., Ltd. ) Serum samples collected separately as the learning sample group. Similarly, 50 healthy individuals who obtained informed consent, as well as glioma (astrocytoma, oligodendroglioma, oligodendrocyte tumor, etc.) Astrocytoma) patients (7 cases of grade II, 13 cases of grade III, and 29 cases of grade IV) and 7 patients of meningioma as benign brain tumor patients were treated with Venoject II vacuum blood collection tube VP-AS109K60 (Terumo Co., Ltd. The serum samples collected separately were used as the verification sample group.

[0290]

[0291] As a sample, 300 μL of serum was obtained ...

reference example 2

[0295]

[0296] From 37 patients with primary malignant lymphoma of the central nervous system, 6 patients with ependymoma, 5 patients with ganglioglioma, and hairy astrocytes without cancer except for brain tumors who obtained informed consent and obtained informed consent. Serum was collected from a total of 51 of 3 tumor patients using Venoject II vacuum blood collection tubes VP-AS109K60 (Terumo Co., Ltd.) to serve as a verification sample group. Subsequent extraction of total RNA and measurement and analysis of gene expression levels were performed in the same manner as in Reference Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a kit or a device for detecting a malignant brain tumor, and a method of detecting the same. The present invention pertains to the following: a kit or a device for detecting a malignant brain tumor, where the kit or device includes a nucleic acid capable of binding specifically to a particular miRNA in a sample from a test subject; and a method for detecting a malignant brain tumor, where the method includes in vitro measurement of the miRNA.

Description

technical field [0001] The present invention relates to a kit or device for detecting a malignant brain tumor comprising a nucleic acid capable of specifically binding to a specific miRNA for examining whether a subject is suffering from a malignant brain tumor, and including measuring the expression of the miRNA using the nucleic acid Quantitative Step-by-Step Detection Method for Malignant Brain Tumors. Background technique [0002] Brain tumors are divided into primary brain tumors that arise from the brain itself, and metastatic brain tumors that metastasize from cancers in other organs to the brain. Primary brain tumors are divided into benign and malignant, and are subdivided according to the cell type that becomes their origin. [0003] Primary brain tumors are mainly classified into gliomas (malignant), primary malignant lymphomas of the central nervous system (malignant), meningiomas (mainly benign), pituitary adenomas (benign), schwannomas ( benign), congenital t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12M1/00C12N15/09C12Q1/6886G01N33/50
CPCC12M1/00C12Q1/68C12N15/09C12N15/113G01N33/50C12Q2600/158C12Q2600/178C12Q1/6834C12Q1/6837C12Q1/6886C12N2310/141
Inventor 吉本真纪子小园聪子河内淳平近藤哲司信正均落谷孝广成田善孝大野诚
Owner TORAY IND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap